

INSTRUCTION DIVISION FIRST SEMESTER 2015-2016 Course Handout (Part II)

Date: 03/08/2015

In-addition to Part -I (General Handout for all courses appended to the time table) this portion gives further specific details regarding the course

Course No : PHA G 617

Course Title : Advanced Drug Delivery Systems

Instructor-in-charge : Dr. DEEPAK CHITKARA

Instructor : Emil Joseph

1. Course Description

A study of physicochemical, biopharmaceutical and physiological factors involved in the design of novel drug delivery systems like mucosal, particulate systems for systemic delivery of bioactive molecules. Special considerations for delivery of protein, peptide and other biological products. In vitro and in vivo evaluation of novel drug delivery systems.

2. Scope and objective of the course:

The prime objective of this course is to impart knowledge of design, development and evaluation of novel drug delivery systems (NDDS). The primary focus would be on integrating the biopharmaceutical, physiochemical and physiological properties for design and development of (NDDS) with due consideration of pharmacological action. Excipients used in design and development of NDDS would be covered exhaustively. Various techniques involved in in vitro and in vivo evaluation of NDDS would be dealt at length. Special impetus would be given to IVIVC.

3. Text Book:

i. Tyle, P. Specialized Drug Delivery Systems- Manufacturing and Production Technology, Marcel Dekker, New York, 1990

4. Reference Book:

- i. Prescott, L.F., and Nimmo, W.S. Novel Drug Delivery, John Wiley & Sons, Chichester, 1989.
- ii. McNally, E. J. Protein Formulation and Delivery, Marcel Dekker, New York, 2000.
- iii. Frokjaer, S., and Hovgaard, L. Pharmaceutical Formulation Development of Peptides and Proteins, Taylor and Francis, London, 2000.

5. Course Plan:

Lect. No.	Learning Objectives	Topics to Covered	Ref. Chap/Sc
			# (Book)
1-2	Overview of NDDS, Opportunities and challenges	General Introduction	T.1 CH.1
3-4		Physicochemical, Biopharmaceutical and Physiological factors important	R.3 CH. 2 &7







BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE, Pilani Pilani Campus

भान पर्म बटा			
	NDDS	for design of NDDS	
5-7	Techniques used for development of	Various Techniques involved in	R.3 CH. 2 &7
	NDDS	development of NDDS	
8-10	Design and Physical	Microparticles	T.1 CH.5
	characterization of particulate drug	Nanoparticles	
	delivery systems		
11-13	Targeted Drug delivery	Various drug delivery systems for	R.3
		site specific targeting	CH.9,25,&32
14-21	Design of transmucosal drug	Buccal and Sublingual	T.1 CH.8, R.2
	delivery systems	Ocular	CH.14 15 16
		Nasal	
		Pulmonary route	
		Transdermal	
22-24	Drug delivery of proteins and	Basic considerations in the design of	T.1 CH.6, R.1
	peptides	Protein/Peptide based delivery	CH.29, R.2
		systems	CH.5
24-31	In vitro Characterization	Various methods and techniques for	These are
		in-vitro drug release and other	advanced
		characterization of NDDS	topics and will
32-34	In vivo Characterization and	Selection of appropriate animal	be covered
	Evaluation	models for evaluation of various	using journal
		NDDS	articles.
35-36	Novel Delivery devices	Various devices for controlled and	Federal
		site specific drug delivery	guidelines
37-38	IVIVC	In vitro in vivo correlation	keep on
39-40	PK/PD modeling	PK/PD modeling	changing so
		-	latest
			guidelines
			would be
			covered.

6. Evaluation Scheme:

Component	Duration	Weightage (%)	Date & Time	Remarks
Mid Term Test	90 min	30	10/10 10:00 -	СВ
			11:30 AM	
Assignment/Lab		35		
Project/Group				
Discussion/Seminar				
Comprehensive	3 Hrs	35	12/12 AN	CB+OB
Exam				

- 7. **Attendance:** Regularity in attendance will be one of the criteria in deciding borderline cases at the time of final grading.
- 8. **Notices**: Pharmacy Notice Board.
- 9. **Chamber Consultation Hour:** To be announced in the class.







BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE, Pilani Pilani Campus

10. **Make-up Policy:** Make-ups are not given as a routine. It is solely dependent on the "genuineness" of the circumstances under which a student fails to appear in a scheduled evaluation component. Prior permission should be sought from the instructor-in-charge in advance.

Instructor-in-charge



